In Q3 2022, big data recruitment in the global pharmaceutical industry fell by 0.67%
The global pharmaceutical industry experienced 0.67% rise in new job postings related to big data in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This is compared to the 0.67% increase in Q3 2021 and a 15% rise versus Q3 20201.
Notably, General and Operations Managers jobs accounted for an 8% share of the global pharmaceutical industry’s big data-related total new job postings in Q3 2022, up 0.37% over the prior quarter.
Big data-related hiring activity is driven by Operations and General Managers
General and Operations Managers topped the list of top big data roles in the pharmaceutical industry. New job postings rose by 0.3% quarter-on-quarter. With a share of 7 percent in Q3 2022 Software and Web Developers, Programmers, and Testers were second, with new job postings rising by 10% over the preceding quarter.
Other notable big data roles include Biological Scientists (6% share in Q3 2022), Database and Network Administrators and Architects (3% share of new job openings).
The top five companies in the pharmaceutical industry were responsible for 2% of all hiring activity
The top companies, in terms of number of new job postings tracked by GlobalData, as of Q3 2022 were Evolent Health , Johnson & Johnson, Intermountain Healthcare and Hastings Center. They combined account for 2% in all big data-related jobs in the pharmaceutical sector.
Evolent Health posted 2,137 jobs in Q3 2022 and registered a rise of 18% over the previous quarter, followed by Johnson & Johnson with 1,404 jobs and a 4% drop. Intermountain Healthcare posted 1,328 jobs and Hastings Center had 935 jobs. CVS Health saw a 4.4% decline and 804 job postings in Q3 2022.
US was the main driver of hiring activity, accounting for 78% percent of total job postings during Q3 2022
In Q3 2022, the US accounted for 78% of all big data-related job openings in the pharmaceutical sector. India was next at 41% and the UK at 3%. The US accounted for 3% more than the 75% it held in Q2 2022.